A New Paradigm for Pediatric AML: Improving the Pipeline for Treatments Targeting Cytogenetic and Molecular Alterations
Cancers · 19.08.2026 · 18 (16) · 2686
DOI: 10.3390/cancers18162686 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.08.2026. Verfasst von Camila Ayerbe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Texas Southwestern, Dallas, TX 77030, USA. Die Arbeit nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pediatric acute myeloid leukemia (AML) is a highly heterogeneous malignancy, with cytogenetic and molecular abnormalities playing a critical role in determining prognosis and guiding treatment decisions. Despite therapeutic advances, patients with high-risk genetic mutations and translocations continue to experience suboptimal outcomes. As new targeted therapies emerge, the treatment of pediatric AML could undergo a paradigm shift, where “one-size-fits-all” chemotherapy is no longer the only frontline approach. Identifying genetic markers inform risk stratification and have greater impact on shaping the therapeutic approach, including the integration of targeted therapies such as FLT3 and menin inhibitors into frontline therapy. Furthermore, pediatric AML treatment options are being driven by recent discoveries in adult AML, broadening their clinical trials to include pediatric patients, in part due to the RACE for Children Act that went into effect in August 2020. This review identifies the most prevalent high-risk cytogenetic lesions in pediatric AML, emphasizing their incidence, prognostic significance, and implications for clinical management. By synthesizing current research on these key genetic abnormalities and their associated therapies, we aim to provide an updated perspective on the evolving landscape of high-risk pediatric AML management that can then lead to the establishment of an agile framework to rapidly evaluate, approve, and deploy novel agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, University of Texas Southwestern, Dallas, TX 77030, USA.
- Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Division of Pediatrics, Leukemia/Lymphoma Section, The University of Texas MD Anderson Cancer Center, Houston, TX 77070, USA.
- Department of Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Children's Cancer Hospital, Houston, TX 77030, USA.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Aaron E Fan, Ryan Scanlan, Reeja Raj, Samanta Catueno, David McCall, Miriam B Garcia, Irtiza N Sheikh, Amber Gibson
Zitieren
APA
Ayerbe, C., Fan, A. E., Scanlan, R., Raj, R., Catueno, S., Ray, A., Aguirre, H., McCall, D., Roth, M., Garcia, M. B., Nunez, C., Sheikh, I. N., Garcia-Manero, G., Cuglievan, B., & Gibson, A. (2026). A New Paradigm for Pediatric AML: Improving the Pipeline for Treatments Targeting Cytogenetic and Molecular Alterations. Cancers, 18(16), 2686. https://doi.org/10.3390/cancers18162686
Vancouver
Ayerbe C, Fan AE, Scanlan R, Raj R, Catueno S, Ray A, et al. A New Paradigm for Pediatric AML: Improving the Pipeline for Treatments Targeting Cytogenetic and Molecular Alterations. Cancers. 2026;18(16):2686. doi:10.3390/cancers18162686
BibTeX
@article{Ayerbe2026,
author = {Ayerbe, Camila and Fan, Aaron E and Scanlan, Ryan and Raj, Reeja and Catueno, Samanta and Ray, Anwesha and Aguirre, Huber and McCall, David and Roth, Michael and Garcia, Miriam B and Nunez, Cesar and Sheikh, Irtiza N and Garcia-Manero, Guillermo and Cuglievan, Branko and Gibson, Amber},
title = {A New Paradigm for Pediatric AML: Improving the Pipeline for Treatments Targeting Cytogenetic and Molecular Alterations},
journal = {Cancers},
year = {2026},
volume = {18},
number = {16},
pages = {2686},
doi = {10.3390/cancers18162686}
}
EUVIMED